MARKET

NBIX

NBIX

Neurocrine Biosciences Inc
NASDAQ
145.69
+1.55
+1.08%
After Hours: 145.69 0 0.00% 16:06 07/19 EDT
OPEN
144.47
PREV CLOSE
144.14
HIGH
146.30
LOW
143.09
VOLUME
600.04K
TURNOVER
0
52 WEEK HIGH
150.39
52 WEEK LOW
94.68
MARKET CAP
14.66B
P/E (TTM)
40.03
1D
5D
1M
3M
1Y
5Y
1D
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
NASDAQ · 18h ago
Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline
Seeking Alpha · 19h ago
NEUROCRINE BIOSCIENCES INC <NBIX.O>: BMO RAISES TARGET PRICE TO $142 FROM $138
Reuters · 21h ago
U.S. RESEARCH ROUNDUP-Anaptysbio, Blackstone, Netflix
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Anaptysbio, Blackstone, Netflix and Domino's Pizza among companies with revised targets. AnptysbIO: JP Morgan raises to overweight from underweight. Blackstone raises target price to $149 from $134.
Reuters · 1d ago
NEUROCRINE BIOSCIENCES LAUNCHES INGREZZA® SPRINKLE (VALBENAZINE) CAPSULES TO EASE ADMINISTRATION FOR PATIENTS EXPERIENCING DYSPHAGIA OR DIFFICULTY SWALLOWING
Reuters · 1d ago
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
NASDAQ · 4d ago
Weekly Report: what happened at NBIX last week (0708-0712)?
Weekly Report · 5d ago
Neurocrine Is Maintained at Overweight by Morgan Stanley
Dow Jones · 07/12 17:11
More
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Webull offers Neurocrine Biosciences, Inc. stock information, including NASDAQ: NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.